Actinogen Targets Mid-November for Xanamem Alzheimer's Trial Results
Bitget2026/10/28 12:51- Actinogen Medical narrowed guidance for final XanaMIA Alzheimer’s trial topline results to mid-November 2026, from November, following database lock.
- The randomized, double-blind phase 2b/3 trial compares oral Xanamem 10 mg with placebo over 36 weeks.
- Enrollment totaled 247 participants across Australia and the United States, selected for elevated plasma pTau181.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Lithium-For-Earth Raises KRW 1.32 Billion in Private Placement
Anthropic "accidentally" leaks IPO documents! Plans to raise $69.3 billion, valuation drops from 2 trillion to 1.3 trillion
Anthropic mistakenly published and then withdrew a prospectus for a planned $69.3 billion fundraising, with its valuation dropping from a peak of $2 trillion to between $1.1 trillion and $1.3 trillion.
Subaru Publishes Transcript of First-Half FYE 2027 Financial Results Presentation
Citi: Occidental Petroleum (OXY.US) Q3 cash flow surpasses expectations, accelerated debt repayment cannot hide concerns over Q4 output
Citi published a research report maintaining Occidental Petroleum's "Neutral" rating, with a target price of $65.
Crypto prices
More
